AnaptysBio
ANAB
129 hedge funds and large institutions have $2.13B invested in AnaptysBio in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 29 reducing their positions, and 13 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 29
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
24% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $13.3M
15% more capital invested
Capital invested by funds: $1.85B → $2.13B (+$278M)
7% more funds holding
Funds holding: 121 → 129 (+8)
0.42% less ownership
Funds ownership: 108.3% → 107.88% (-0.42%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$26.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.2M |
| 3 |
Millennium Management
New York
|
+$13.4M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$9.17M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$38.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.8M |
| 3 |
Morgan Stanley
New York
|
-$9.97M |
| 4 |
AG
Artal Group
Luxembourg
|
-$9.57M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.48M |
ANAB Hedge Fund Activity: Q1 2019 in Review
129 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2019, worth a combined $2.13B — up 15% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ANAB positions and 13 closed out — a net gain of 9 holders — while 53 added to existing stakes and 29 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $26.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $38.6M sold.
- 129 institutional investors held AnaptysBio (ANAB) as of Q1 2019, up from 121 in Q4 2018.
- Funds reported $2.13B of AnaptysBio stock for Q1 2019, up 15% quarter-over-quarter.
- 22 funds opened new AnaptysBio positions in Q1 2019 and 13 closed out, a net change of +9 holders.
- The largest AnaptysBio buyer in Q1 2019 was Adage Capital Partners, an estimated $26.1M added.
- The largest AnaptysBio seller in Q1 2019 was PFM Health Sciences, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2019.